Spark Therapeutics commits to an ongoing stability program post-approval. At least one commercial batch of drug substance will be placed on stability each year. The protocol follows ICH Q5C guidelines, with testing at 0, 3, 6, 9, 12, 18, 24, and 36 months. We also commit to completing the ongoing stability study of the HEK293 Master Cell Bank (MCB).